AUSTIN, Texas and DURHAM, N.C. - Shattuck Labs Inc. (NASDAQ:STTK) announced today Phase 1 clinical trial results for SL-325, a DR3 blocking antibody designed to inhibit the TL1A pathway for treating inflammatory and immune-mediated diseases.
The first-in-human, randomized, placebo-controlled trial enrolled 72 healthy volunteers across six single-ascending dose cohorts ranging from 0.1 mg/kg to 30.0 mg/kg and three multiple-ascending dose cohorts from 1 mg/kg to 10 mg/kg, according to a press release statement.
Antidrug antibodies to SL-325 were detected in 3.7% of participants who received the drug. In these two participants, antibodies were low titer and showed no impact on pharmacokinetics or receptor occupancy. Complete DR3 occupancy was observed at doses of 0.1 mg/kg and higher in all participants. Complete inhibition of TL1A binding was sustained for more than 10 weeks, with extended modeling suggesting inhibition may last greater than three months at doses above 1 mg/kg.
The drug was well tolerated at all dose levels with no serious treatment-emergent adverse events or serious adverse events reported. All treatment-related adverse events were Grade 1 and occurred in 12 participants. No evidence of DR3 agonism or lymphocyte proliferation was observed at any dose level.Despite the positive trial results, Shattuck’s stock fell 18.9% over the past week, though shares remain up 302% over the past year. According to InvestingPro analysis, the company holds more cash than debt on its balance sheet, providing financial flexibility for its clinical programs.
The company plans to initiate the RECEPTIVE-CD1 Phase 2b clinical trial in patients with Crohn’s disease in the third quarter of 2026. The trial will enroll approximately 174 patients across the United States, Canada, and Europe, with a 12-week induction period followed by a 40-week maintenance period. The primary endpoint of endoscopic response at 12 weeks is expected to be disclosed in the first half of 2028.Shattuck carries a market capitalization of $351 million, with analysts maintaining a Strong Buy consensus and price targets ranging from $7 to $18. InvestingPro data suggests the stock is currently overvalued relative to its Fair Value estimate. For deeper insights into Shattuck’s financial health and access to 10 additional ProTips, visit InvestingPro.
Shattuck’s bispecific product candidate SL-846 is currently in IND-enabling toxicology studies, with Phase 1 initiation expected in the first half of 2027.
In other recent news, Shattuck Labs, Inc. announced that it will host an investor call and webcast to present Phase 1 clinical data for its DR3-blocking antibody, SL-325. The presentation is scheduled for June 8, 2026, at 8:00 a.m. ET. The company will discuss various aspects of the clinical trial, including safety, tolerability, pharmacokinetics, receptor occupancy, pharmacodynamics, and immunogenicity results. Additionally, Shattuck Labs plans to provide an update on its development pipeline. This event is expected to offer investors insights into the progress of SL-325 and the company’s research efforts. These recent developments are part of Shattuck Labs’ ongoing efforts to advance its clinical programs.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Most traders can read a chart. The hard part is the moment: entry window open, pattern forming, and you're still waiting for more confirmation. That's the conviction gap — and our chart analysis closes it. Unlike other AIs that just read data, our Vision AI literally "sees" your charts and hands you a complete trading plan: entry, stop-loss, and profit target in under 60 seconds. Know exactly what to do next, every time.